Clinical Trials Logo
  1. Home
  2. Severe Malaria
  3. NCT04516317

Very Severe Malaria Treated by Intravenous Artesunate — Palustar  

Severe Malaria Clinical Trial

Official title:
Very Severe Malaria Treated by Intravenous Artesunate: Epidemiology, Management, Outcome and Prognostic

Clinical Trial Summary

In endemic areas, Plasmodium falciparum malaria exacts a huge public health toll, causing close to half a million deaths each year. In non-endemic industrialized areas, imported malaria may develop. In France, around 5000 imported cases occured annually, including 10-15% of severe malaria. The criteria for defining severe malaria in endemic areas are established by the World Health Organization (WHO), and have been adjusted for severe imported malaria. In France, in order to optimize management, severe imported malaria is separated into two groups: very severe malaria (VSM) and less severe malaria (LSM). Briefly VSM included coma and/or shock and/or respiratory failure and/or acidosis and/or hyperlactatemia and/or death during hospitalization. In France, severe imported malaria is treated with intravenous artesunate. Little is known about the management of imported VSM in the ICU with intravenous artesunate. In a French national multicentric retrospective frame, the main objective of the present study is to describe in detail: epidemiology, management, outcome and prognostic of very severe imported malaria treated with intravenous artesunate during the period 2011-2019. The second objective is to retrospectively compare two groups : VSM treated with intravenous artesunate in the ICU during 2011-2019 versus VSM treated with intravenous quinine in the ICU during 2000-2010.

Clinical Trial Description

See Brief Summary ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04516317
Study type Observational
Source Versailles Hospital
Contact
Status Completed
Phase
Start date August 10, 2020
Completion date March 22, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT01955382 - Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria Phase 2
Not yet recruiting NCT01122134 - Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment N/A
Recruiting NCT04675931 - To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Phase 2
Recruiting NCT05685875 - Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
Completed NCT02451904 - Severe and Cerebral Malaria Investigated Through Host Metabolomics
Completed NCT04037332 - Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Completed NCT00341003 - Severe Malaria and Anti-malarial Drug Resistance in Cambodia N/A
Completed NCT01255215 - Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial Phase 1/Phase 2
Completed NCT05140278 - Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate Phase 2
Recruiting NCT05711485 - Platelet-Directed Whole Blood Transfusion Strategy for Malaria N/A
Completed NCT04473768 - Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
Completed NCT04176029 - Lung Ultrasound in Children With Severe Malaria
Recruiting NCT06064591 - Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Recruiting NCT04251351 - Effect of Paracetamol on Kidney Function in Severe Malaria Phase 3
Completed NCT00342043 - Examination of Protective Factors Against Severe Malaria N/A
Completed NCT01828333 - Malaria Treatment With Injectable ArteSunate N/A